{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-001020","form_type":"8-K","ticker":"MGTX","cik":"0001735438","company_name":"MeiraGTx Holdings plc","filed_at":"2024-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.340442+00:00","generated_at":"2026-06-06T03:30:02.432469+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MeiraGTx receives $50M milestone from Janssen for bota-vec Phase 3 extension study","bullets":["$50M milestone triggered by initiation of LUMEOS extension study for bota-vec (XLRP gene therapy).","Additional $15M in near-term milestone payments expected later in 2024 from Janssen.","Up to $285M further payments on first U.S./EU commercial sales and manufacturing tech transfer.","Commercial supply agreement with J&J for bota-vec manufacturing expected to generate ongoing revenue."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-001020","json":"https://secwatch.observer/filing/0001558370-24-001020.json","markdown":"https://secwatch.observer/filing/0001558370-24-001020.md","text":"https://secwatch.observer/filing/0001558370-24-001020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1735438/000155837024001020/0001558370-24-001020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1735438/000155837024001020/mgtx-20240213x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T03:30:02.432469+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}